Angela Verrecchio’s practice focuses on life sciences patent litigation and also includes prelitigation due diligence, client counseling and opinion work. Ms. Verrecchio’s practice encompasses a variety of technologies, including complex biotechnology and chemical inventions, such as monoclonal antibodies, biosimilars, vaccines, pharmaceuticals and DNA diagnostics; and medical devices, such as hemostatic devices, surgical sutures, surgical staplers and blood glucose monitoring devices. Ms. Verrecchio also has significant experience representing clients in Abbreviated New Drug Application (ANDA) litigations. Her experience ranges from prelitigation due diligence review through trial and appeals.
Practice & Background
Ms. Verrecchio has significant trial experience, including before district courts and the International Trade Commission (ITC). Most recently, Ms. Verrecchio has been representing a major pharmaceutical company and its partners in three separate litigations against other major pharmaceutical companies over therapeutic PD-1 and PD-L1 antibodies. She was recently part of a team that sued another major pharmaceutical company over its PD-1 therapeutic antibody, resulting in a favorable settlement for the firm’s clients of hundreds of millions of dollars and an ongoing royalty.
Ms. Verrecchio’s other current matters include representing multiple defendants in ANDA litigation involving a narcotic pharmaceutical product and representing a patent holder in ANDA litigation over a treatment for schizophrenia.
She was part of a trial team defending a medical device maker against claims of patent infringement before the ITC. After trial, the case was settled on favorable terms for the client. Ms. Verrecchio was also a member of the trial team that secured a jury verdict for Janssen in a patent case involving therapeutic antibody technology. The jury returned a verdict for the defendant, finding the asserted claims invalid for obviousness, lack of written description and lack of enablement. Ms. Verrecchio was also a member of the trial team that won a $1.67 billion verdict on behalf of Centocor Ortho Biotech, Inc. and New York University in the Eastern District of Texas. That case involved an infringement suit against Abbott Laboratories for its blockbuster drug Humira®. The jury returned a verdict finding that the patent-in-suit willfully infringed and was not invalid. Bloomberg reported the $1.67 billion verdict as the largest patent jury verdict in U.S. history.
Ms. Verrecchio has a solid grounding in science, with an M.S. in biomedical chemistry from Thomas Jefferson University and a B.S. in biochemistry from the Philadelphia College of Pharmacy and Science (now the University of the Sciences in Philadelphia). While pursuing her graduate degree, Ms. Verrecchio served as a research technician at Thomas Jefferson University’s Cardeza Foundation for Hematologic Research.
Ms. Verrecchio is an active member of the Philadelphia Intellectual Property Law Association and is a former president of the organization.
Ms. Verrecchio’s recent engagements include:
- representing a pharmaceutical company in ANDA litigation over treatment for schizophrenia
- representing pharmaceutical companies in patent infringement suits involving PD-1 and PD-L1 antibodies (D. Del.)
- representing an innovator pharmaceutical company in a patent infringement suit involving monoclonal antibodies, brought under the Biologics Price Competition and Innovation Act (D. Mass.)
- representing a pharmaceutical company in defending against claims in multiple ANDA litigations involving oxycodone (D. Del.)
- representing pharmaceutical companies in patent infringement suits involving PD-1 antibodies (D. Del.); succeeded in obtaining a favorable settlement for client
- representing a pharmaceutical company in a patent infringement suit involving a meningitis B vaccine; succeeded in obtaining a favorable settlement resolving the matter
- representing biotech companies in a patent infringement suit involving the first-ever Food and Drug Administration (FDA) approved monoclonal antibody to treat high cholesterol (D. Del.)
- representing a leading supplier of DNA detection systems in a patent infringement suit (D. Del.)
- representing a pharmaceutical company in defending against claims in ANDA litigation involving oxycodone (S.D.N.Y.); succeeded in invalidating key patents, which was affirmed on appeal
- representing a medical device manufacturer in a patent infringement suit in district court and the ITC; succeeded in obtaining favorable settlements from the plaintiff (N.D. Il.; ITC)
- representing a pharmaceutical company in a series of patent infringement suits involving a monoclonal antibody therapeutic to IL-12 (D. Mass.); succeeded in obtaining a district court verdict of invalidity, which was affirmed on appeal
- representing a pharmaceutical company in a patent infringement suit involving a method of using monoclonal antibodies for therapeutic treatment (D. Mass.); succeeded in obtaining a favorable settlement for the client
- representing a pharmaceutical company in challenging a biotechnology patent (C.D. Calif.); succeeded in obtaining a settlement saving the client tens of millions of dollars in royalties.
Awards & Accolades
- recognized by Best Lawyers in America as a leading practitioner in the area of IP litigation in 2014-2016 and 2018
- named a “Rising Star” in the field of IP litigation by Philadelphia magazine in 2008, 2010, 2011 and 2012.
- Supreme Court and Federal Circuit Year in Review (May 2016 to May 2017), Philadelphia Intellectual Property Law Association, Year-in-Review Meeting, May 17, 2017
- presenter, Patent Litigation, Philadelphia Intellectual Property Law Association, Year-End Meeting, May 3, 2016
- Structuring and Negotiating Patent Litigation Settlements, Association of Corporate Counsel Greater Philadelphia/Delaware Valley’s Intellectual Property Law CLE Institute, July 15, 2015
- The Objective Prong of Willfulness Is a Matter of Law: Bard Peripheral Vascular, Inc. v. W.L. Gore & Assoc., Inc. (Fed. Cir. 2012), 29th Annual Joint Patent Practice Seminar, March 2013
- CAFC Litigation Review, Philadelphia Intellectual Property Law Association’s 26th Annual Review of the Intellectual Property Decisions of the U.S. Court of Appeals for the Federal Circuit, May 2011.